<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487851</url>
  </required_header>
  <id_info>
    <org_study_id>2006/2:3</org_study_id>
    <nct_id>NCT00487851</nct_id>
  </id_info>
  <brief_title>Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer</brief_title>
  <official_title>Endoscopic Strategy Versus Surgical by Pass in Nonresectable Periampullary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study comparing endoscopic stent insertion strategy versus double-bypass surgery&#xD;
      in non-resectable periampullary cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experience shows that patients with advanced periampullary cancer suffer not only from&#xD;
      jaundice but in 25 -30% of cases also duodenal stricture with nausea, vomiting and&#xD;
      nutritional difficulties. Ten years ago, the only palliative treatment for these patients was&#xD;
      a bypass operation for bile flow and intestinal passage. This operation was often associated&#xD;
      with a high morbidity. Developments in endoscopic treatments allow palliation with lower&#xD;
      morbidity. However, stent treatment is not free of problems like stent dysfunction. During&#xD;
      the last ten years, anesthesia and surgical techniques have developed which allow lower&#xD;
      postoperative morbidity compared to earlier treatments. A total of 70 patients were&#xD;
      randomized to surgery with hepaticojejunostomy on Roux loop and gastrojejunostomy or&#xD;
      endoscopic treatment with self-expanding metallic stent in the bile duct and so-called&#xD;
      duodenal stent. Based on the inclusion of 70 patients, we expected a 20% difference in some&#xD;
      of the primary variables with a power of 80%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn&#xD;
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome consist of a composite score (i.e. number of hospitalizations, episodes of cholangitis, degree of jaundice, other complications requiring therapeutic interventions). Secondary outcome are QoL,hospital stay and health economic burden.</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Biliary Tract Neoplasms</condition>
  <condition>Duodenal Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic treatment strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical treatment strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>hepaticojejunostomy and gastroenterostomy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic strategy</intervention_name>
    <description>Stent insertion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a locally advanced periampullary neoplastic process with extrahepatic&#xD;
             bile duct obstruction.&#xD;
&#xD;
          -  The patient tumor burden and general condition should be such that treatment related&#xD;
             morbidity and mortality is calculated as &quot;reasonable&quot; and both treatment strategies&#xD;
             are considered &quot;applicable&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non consent.&#xD;
&#xD;
          -  The patients' general condition will not tolerate either treatment (strategy).&#xD;
&#xD;
          -  Previous laparotomy or laparoscopy.&#xD;
&#xD;
          -  Life expectancy &lt; 3 months.&#xD;
&#xD;
          -  Inability to participate (language, social, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farshad Frozanpor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska institut Huddinge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinksa university hospital</name>
      <address>
        <city>Huddinge</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2007</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Farshad Frozanpor</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Pancreatic</keyword>
  <keyword>cancer</keyword>
  <keyword>Periampullay</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Biliary</keyword>
  <keyword>Duodenal</keyword>
  <keyword>Jaundice</keyword>
  <keyword>obstruction</keyword>
  <keyword>pancreas cancer</keyword>
  <keyword>Pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Duodenal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

